<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang Y</submitter><funding>National Natural Science Foundation of China</funding><funding>National Key Research and Development Program of China</funding><pagination>114701</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9715986</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>283</volume><pubmed_abstract>&lt;h4>Ethnopharmacological relevance&lt;/h4>Xuanfei Baidu Decoction (XFBD), one of the "three medicines and three prescriptions" for the clinically effective treatment of COVID-19 in China, plays an important role in the treatment of mild and/or common patients with dampness-toxin obstructing lung syndrome.&lt;h4>Aim of the study&lt;/h4>The present work aims to elucidate the protective effects and the possible mechanism of XFBD against the acute inflammation and pulmonary fibrosis.&lt;h4>Methods&lt;/h4>We use TGF-β1 induced fibroblast activation model and LPS/IL-4 induced macrophage inflammation model as in vitro cell models. The mice model of lung fibrosis was induced by BLM via endotracheal drip, and then XFBD (4.6 g/kg, 9.2 g/kg) were administered orally respectively. The efficacy and molecular mechanis</pubmed_abstract><journal>Journal of ethnopharmacology</journal><pubmed_title>Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway.</pubmed_title><pmcid>PMC9715986</pmcid><funding_grant_id>2020YFA0708000</funding_grant_id><funding_grant_id>82074032</funding_grant_id><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Xue Z</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Chang Y</pubmed_authors><pubmed_authors>Sang X</pubmed_authors><pubmed_authors>Qin H</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Gao X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Shao R</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway.</name><description>&lt;h4>Ethnopharmacological relevance&lt;/h4>Xuanfei Baidu Decoction (XFBD), one of the "three medicines and three prescriptions" for the clinically effective treatment of COVID-19 in China, plays an important role in the treatment of mild and/or common patients with dampness-toxin obstructing lung syndrome.&lt;h4>Aim of the study&lt;/h4>The present work aims to elucidate the protective effects and the possible mechanism of XFBD against the acute inflammation and pulmonary fibrosis.&lt;h4>Methods&lt;/h4>We use TGF-β1 induced fibroblast activation model and LPS/IL-4 induced macrophage inflammation model as in vitro cell models. The mice model of lung fibrosis was induced by BLM via endotracheal drip, and then XFBD (4.6 g/kg, 9.2 g/kg) were administered orally respectively. The efficacy and molecular mechanis</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-04T19:49:48.247Z</modification><creation>2025-04-04T19:49:48.247Z</creation></dates><accession>S-EPMC9715986</accession><cross_references><pubmed>34606948</pubmed><doi>10.1016/j.jep.2021.114701</doi></cross_references></HashMap>